We hypothesized that treatment with a topical protease inhibitor, Saquinavir, in transgenic mice would prevent the progression of anal dysplasia to anal cancer while leading to inconsistent E6, E7, p53, and pRb signaling without significant systemic absorption or deleterious side effects. Here, TP53 is linked to anal carcinoma.